IN2015DN04089A - - Google Patents

Info

Publication number
IN2015DN04089A
IN2015DN04089A IN4089DEN2015A IN2015DN04089A IN 2015DN04089 A IN2015DN04089 A IN 2015DN04089A IN 4089DEN2015 A IN4089DEN2015 A IN 4089DEN2015A IN 2015DN04089 A IN2015DN04089 A IN 2015DN04089A
Authority
IN
India
Prior art keywords
enantiomers
signifies
alkyl alkylaryl
alkylheteroaryl
proviso
Prior art date
Application number
Other languages
English (en)
Inventor
Da Silva Patrício Manuel Vieira Araújo Soares
Maria João Macedo Da Silva Bonifácio
Original Assignee
BIAL PORTELA & Cª S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIAL PORTELA & Cª S A filed Critical BIAL PORTELA & Cª S A
Publication of IN2015DN04089A publication Critical patent/IN2015DN04089A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4089DEN2015 2012-11-14 2013-11-14 IN2015DN04089A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261726119P 2012-11-14 2012-11-14
PCT/PT2013/000065 WO2014077715A1 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Publications (1)

Publication Number Publication Date
IN2015DN04089A true IN2015DN04089A (enExample) 2015-10-09

Family

ID=49759506

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4089DEN2015 IN2015DN04089A (enExample) 2012-11-14 2013-11-14

Country Status (23)

Country Link
US (3) US9604970B2 (enExample)
EP (1) EP2919780B1 (enExample)
JP (1) JP6373275B2 (enExample)
KR (1) KR102259938B1 (enExample)
CN (1) CN105025895B (enExample)
AU (1) AU2013345494B2 (enExample)
BR (1) BR112015010969B1 (enExample)
CA (1) CA2890920C (enExample)
CY (1) CY1120953T1 (enExample)
DK (1) DK2919780T3 (enExample)
ES (1) ES2693025T3 (enExample)
HR (1) HRP20181651T1 (enExample)
IN (1) IN2015DN04089A (enExample)
LT (1) LT2919780T (enExample)
MX (1) MX355422B (enExample)
PL (1) PL2919780T3 (enExample)
PT (1) PT2919780T (enExample)
RS (1) RS57874B1 (enExample)
RU (1) RU2718055C2 (enExample)
SI (1) SI2919780T1 (enExample)
SM (1) SMT201800560T1 (enExample)
TR (1) TR201815850T4 (enExample)
WO (1) WO2014077715A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2919780T3 (en) 2012-11-14 2018-11-26 Bial Portela & Ca Sa 1,3-Dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
GB201810395D0 (en) 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
CN118598820B (zh) * 2024-02-06 2025-07-08 石家庄四药有限公司 一种二苯基三嗪类化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623107B2 (ja) * 1990-11-16 1994-03-30 帝人株式会社 プロスタサイクリン類を有効成分とする薬学的組成物
ES2201104T3 (es) * 1994-04-26 2004-03-16 Roche Palo Alto Llc Derivados de benzociclohexilimidazoltiona.
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
GB0600709D0 (en) * 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
GB0700635D0 (en) * 2007-01-12 2007-02-21 Portela & Ca Sa Therapy
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
JP2011506315A (ja) * 2007-12-05 2011-03-03 バイアル−ポルテラ アンド シーエー,エス.エー. 新たな塩、及び結晶形
AU2008347005B2 (en) * 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
AR070841A1 (es) * 2008-03-13 2010-05-05 Bial Portela & Ca Sa Proceso de hidrogenacion catalitica asimetrica
AR071632A1 (es) * 2008-05-06 2010-06-30 Bial Portela & Ca Sa Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa"
DE102008054205A1 (de) * 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie
PT2655363T (pt) * 2010-12-22 2017-07-13 Bial-Portela & Ca S A Formas cristalinas e processos para a sua preparação
DK2919780T3 (en) 2012-11-14 2018-11-26 Bial Portela & Ca Sa 1,3-Dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Also Published As

Publication number Publication date
HK1215393A1 (en) 2016-08-26
HRP20181651T1 (hr) 2018-12-14
JP2016504286A (ja) 2016-02-12
AU2013345494B2 (en) 2018-03-22
MX355422B (es) 2018-04-18
RS57874B1 (sr) 2018-12-31
US9604970B2 (en) 2017-03-28
US20170369477A1 (en) 2017-12-28
CA2890920C (en) 2020-12-15
CA2890920A1 (en) 2014-05-22
SI2919780T1 (sl) 2018-12-31
LT2919780T (lt) 2018-11-12
PL2919780T3 (pl) 2019-01-31
CN105025895A (zh) 2015-11-04
JP6373275B2 (ja) 2018-08-15
MX2015005910A (es) 2015-08-10
US20190241545A1 (en) 2019-08-08
KR20150084022A (ko) 2015-07-21
PT2919780T (pt) 2018-11-13
CN105025895B (zh) 2019-02-26
EP2919780B1 (en) 2018-08-01
ES2693025T3 (es) 2018-12-07
TR201815850T4 (tr) 2018-11-21
RU2718055C2 (ru) 2020-03-30
KR102259938B1 (ko) 2021-06-03
DK2919780T3 (en) 2018-11-26
CY1120953T1 (el) 2020-05-29
SMT201800560T1 (it) 2019-01-11
US20150299172A1 (en) 2015-10-22
WO2014077715A1 (en) 2014-05-22
BR112015010969A2 (pt) 2017-08-22
RU2015120164A (ru) 2017-01-10
AU2013345494A1 (en) 2015-05-14
US10308640B2 (en) 2019-06-04
EP2919780A1 (en) 2015-09-23
BR112015010969B1 (pt) 2020-05-26

Similar Documents

Publication Publication Date Title
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MX375718B (es) [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
ES2531324T3 (es) Intermedio para producir un derivado de gamma-aminoácido bicíclico
TW200612958A (en) Substituted imidazole derivatives
MX2007004699A (es) Derivados de indol y bencimidazol.
GB0708818D0 (en) Compounds
TW200602043A (en) Use of indazolecarboxamide derivatives for preparing a medicinal product intended for the treatment and prevention of malaria
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
TW200716084A (en) Methods for treating sleep-wake disorders
MY178106A (en) 1,4-butanediol-containing composition
AR035521A1 (es) Derivados de 3-indolina y composicion farmaceutica que los comprende
MX2015014921A (es) Compuesto de acido dicarboxilico.
PH12018502012B1 (en) Griseofulvin compound
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
CY1120953T1 (el) Παραγωγα 1,3-διυδροϊμιδαζολο-2-θειονης για χρηση στην αγωγη πνευμονικης αρτηριακης υπερτασης και πνευμονικης βλαβης
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
CR20130476A (es) Derivados de pirazolidin-3-ona
BR112015011974A2 (pt) derivados de azaquinazolina carboxamida
MX2009010225A (es) Nuevos compuestos 707 y sus usos.
IN2014CN01217A (enExample)
EA201491878A1 (ru) Замещенные ксантиновые производные
PH12014500414A1 (en) Oral care compositions
MX2009007329A (es) 1,3-dihidroimidazoles para tratar trastornos cardiovasculares.
MX2015008399A (es) Derivado de benzoazepina novedoso y uso medico del mismo.